Valneva's Chikungunya Vaccine Candidate - VLA 1553
Valneva Initiated a Phase 1 Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya.
Pre-clinical data has shown that Valneva’s live attenuated vaccine candidate is safe and has the potential to provide long term protection against chikungunya after a single immunization.
Valneva initiated a Phase 1 clinical trial in the US to evaluate the safety and immunogenicity of VLA1553, its live-attenuated vaccine candidate against chikungunya.
The Phase 1 clinical trial is a randomized, observer-blinded, dose-escalation, multi-center study. It will investigate three different dose levels of VLA1553 in approximately 120 healthy adults vaccinated with a single-shot immunization. First data from the trial are expected to be available early 2019.
There is currently no antiviral treatment for CHIKV infection and no licensed vaccine to prevent the disease.
The global market for a chikungunya vaccine is estimated at approximately
€500 million annually1
1 Company estimate supported by independent market studies